Kenya: Pharmaceutical VAT Exemptions Delay Threatens Supply Chain

• Kenyan pharmaceutical manufacturers are operating at approximately 30% capacity due to delays in processing VAT exemptions.
• The Federation of Kenya Pharmaceutical Manufacturers warns these delays could disrupt the supply of medicines and healthcare products.
• The issue stems from the Finance Act, 2026, which reclassified pharmaceutical inputs from zero-rated to VAT-exempt.
• Manufacturers now face cumbersome consignment-by-consignment approval for exemptions, replacing a simpler product list approval system.
• The industry imports at least 500 containers monthly, making individual consignment approvals impractical and leading to significant bottlenecks.

The persistent Kenya pharmaceutical VAT exemptions delay directly impacts the nation's healthcare supply chain, underscoring significant compliance and operational risks for pharmaceutical companies.

Pharmaceutical manufacturers in Kenya are currently facing significant operational challenges, leading to warnings of potential disruptions across the nation's healthcare sector. The Federation of Kenya Pharmaceutical Manufacturers (FKPM) has voiced concerns that ongoing administrative delays in processing crucial VAT exemptions could severely impede the production and supply of vital medicines and other healthcare products.

Manufacturers are reportedly operating at a drastically reduced capacity, estimated at approximately 30% of their potential. This substantial decrease in output is directly attributed to the prolonged Kenya pharmaceutical VAT exemptions delay, which is hindering their ability to procure necessary inputs efficiently. The industry emphasizes that these exemptions are critical for maintaining a stable and uninterrupted supply chain for essential healthcare goods.

The root of the current predicament lies in legislative changes introduced by the Finance Act, 2026. This act reclassified various inputs, raw materials, and packaging materials essential for pharmaceutical manufacturing, transitioning them from a zero-rated status to VAT-exempt. While intended to provide relief, the implementation has introduced significant procedural hurdles.

Manufacturers now contend with a cumbersome approval process for these exemptions. Instead of the previous system, which allowed for the approval of a comprehensive list of products, exemptions are now being processed on a consignment-by-consignment basis. Given that the industry imports at least 500 containers each month, this shift to individual approvals for every consignment is proving highly impractical and has become a major bottleneck in the Kenya pharmaceutical supply chain.

The Federation of Kenya Pharmaceutical Manufacturers has urgently called upon the government to streamline these administrative procedures. Their plea is to ensure that manufacturers can access the necessary VAT exemptions without enduring prolonged administrative delays, which are currently creating substantial compliance risks and hindering efficient operations.

The manufacturers assert that these ongoing disruptions pose a dual threat to Kenya. Firstly, they jeopardize the operational viability of the pharmaceutical industry itself, impacting businesses and investments. More critically, these delays threaten the consistent availability of essential healthcare products for the Kenyan populace, raising concerns about public health outcomes.

The persistent Kenya pharmaceutical VAT exemptions delay directly impacts the nation's healthcare supply chain, underscoring significant compliance and operational risks for pharmaceutical companies. This situation necessitates a proactive assessment of supply chain vulnerabilities and potential engagement with regulatory bodies like the Kenya Revenue Authority to mitigate disruption.

Ultimately, the current administrative hurdles, including VAT exemption processing delays, could lead to a scarcity of critical medicines and other Kenya healthcare products VAT-exempt items, affecting public health across the country. Addressing these issues promptly is crucial to safeguard both the pharmaceutical sector and the well-being of Kenyans.

This development signals significant operational and compliance risks for pharmaceutical companies in Kenya due to administrative delays in VAT exemption processing. Legal and compliance teams should proactively assess supply chain vulnerabilities, advise on potential engagement with the Kenya Revenue Authority, and monitor for policy clarifications or changes to mitigate disruption.

Source: Original reporting via Capital FM